Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?-Reference-Cited by-同舟云学术

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?

Published:2016-09-19 Issue:10 Volume:5 Page:505-515
ISSN:2163-8306
Container-title:CPT: Pharmacometrics & Systems Pharmacology
language:en
Short-container-title:CPT Pharmacometrics Syst. Pharmacol.

Author:

Templeton IE¹,Chen Y¹,Mao J¹,Lin J²,Yu H³,Peters S⁴,Shebley M⁵,Varma MV²

Affiliation:

1. GenentechSouth San Francisco California USA

2. Pfizer Inc.Groton Connecticut USA

3. Boehringer Ingelheim PharmaceuticalsRidgefield Connecticut USA

4. AstraZenecaMölndal Sweden

5. AbbVie Inc.North Chicago Illinois USA

Publisher

Wiley

Subject

Pharmacology (medical),Modeling and Simulation

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12110

Reference72 articles.

1. Cisapride-Cimetidine Interaction

2. Systems Analysis of Adverse Drug Events

3. Torsades de Pointes Occurring in Association With Terfenadine Use

4. A Combined Model for Predicting CYP3A4 Clinical Net Drug-Drug Interaction Based on CYP3A4 Inhibition, Inactivation, and Induction Determined in Vitro

5. Intracellular Drug Concentrations and Transporters: Measurement, Modeling, and Implications for the Liver

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening of 16 major drug glucuronides for time-dependent inhibition of nine drug-metabolizing CYP enzymes – detailed studies on CYP3A inhibitors;European Journal of Pharmaceutical Sciences;2024-07

2. Dose Optimization Informed by PBPK Modeling: State‐of‐the Art and Future;Clinical Pharmacology & Therapeutics;2024-04-30

3. Quantitative prediction of transporter-mediated drug-drug interactions using the mechanistic static pharmacokinetic (MSPK) model;Drug Metabolism and Pharmacokinetics;2024-02

4. Evaluation of the potential impact on pharmacokinetics of various cytochrome P450 substrates of increasing IL‐6 levels following administration of the T‐cell bispecific engager glofitamab;CPT: Pharmacometrics & Systems Pharmacology;2023-12-14

5. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3Ain vitro;Drug Metabolism and Disposition;2022-11-29